for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ChemoCentryx Inc

CCXI.OQ

Latest Trade

7.65USD

Change

0.00(0.00%)

Volume

69,652

Today's Range

7.60

 - 

8.03

52 Week Range

6.17

 - 

14.96

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.65
Open
7.73
Volume
69,652
3M AVG Volume
8.74
Today's High
8.03
Today's Low
7.60
52 Week High
14.96
52 Week Low
6.17
Shares Out (MIL)
58.25
Market Cap (MIL)
451.44
Forward P/E
-7.41
Dividend (Yield %)
--

Latest Developments

More

Chemocentryx Posts Q2 Revenue Of $7.2 Million Versus $15 Million

ChemoCentryx Reports Qtrly Loss Per Share $0.23

ChemoCentryx Says Co Sold 4.8 Mln Shares Of Its Common Stock Pursuant To Its Equity Distribution Agreement With Piper Jaffray On March 25

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ChemoCentryx Inc

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Industry

Biotechnology & Drugs

Contact Info

850 Maude Ave

+1.650.2102900

http://www.chemocentryx.com/

Executive Leadership

Thomas J. Schall

Chairman of the Board, President, Chief Executive Officer

Susan M. Kanaya

Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary, IR Contact Officer

Rajinder Singh

Senior Vice President - Research

Markus J. Cappel

Chief Business Officer, Treasurer

Thomas A. Edwards

Independent Director

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.860

2017

0.360

2018

-0.760

2019(E)

-1.085
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.35
Price To Book (MRQ)
6.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
27.62
LT Debt To Equity (MRQ)
27.62
Return on Investment (TTM)
-31.36
Return on Equity (TTM)
-22.35

Latest News

Latest News

BRIEF-Vifor Pharma Increases Equity Investment In ChemoCentryx

* INCREASES EQUITY STAKE IN CHEMOCENTRYX FROM 6.6% TO 21.2% Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million

* CHEMOCENTRYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million

* CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Chemocentryx Secures Up To $100 Million In New Capital Commitments

* CHEMOCENTRYX SECURES UP TO $100 MILLION IN NEW CAPITAL COMMITMENTS

BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review

* AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

BRIEF-Chemocentryx reports Q3 revenue $9.0 million

* Chemocentryx reports third quarter 2017 financial results and recent highlights

BRIEF-ChemoCentryx qtrly basic and diluted net loss per share $0.19

* ChemoCentryx reports second quarter 2017 financial results and recent highlights

BRIEF-Chemocentryx Q1 revenue $8.2 million

* Chemocentryx Inc- Expects to utilize cash and cash equivalents between $50 million and $55 million in 2017

BRIEF-Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease

* Chemocentryx receives fda orphan drug designation for avacopan in the treatment of debilitating kidney disease c3 glomerulopathy (c3g)

BRIEF-Chemocentryx reports Q4 revenue of $4.9 mln

* Chemocentryx Inc - company expects to utilize cash and cash equivalents between $50 million and $55 million in 2017

BRIEF-Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement

* Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases

BRIEF-Chemocentryx reports Q3 loss per share $0.15

* Chemocentryx reports third quarter 2016 financial results and provides corporate update

BRIEF-Chemocentryx reports presentation of positive data from ongoing pilot phase II trial of CCX168

* Chemocentryx announces presentation of positive data from ongoing pilot phase II trial of CCX168 (avacopan) in atypical hemolytic uremic syndrome (AHUS) at ASN kidney week 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up